Cipla enters into strategic agreement with BioQ Pharma

07 Jan 2016 Evaluate

Cipla has entered into a strategic distribution, supply and development agreement with the US-based BioQ Pharma for registration and commercialisation of the latter’s Ropivacaine infusion system, used in treating post-operative pain, in India.

The Ropivacaine infusion system is pre-filled, ready to use at the point of care, and intended to provide a safer, more efficient continuous-infusion post-operative pain solution. BioQ Pharma’s unit-dose infusion pharmaceuticals have been developed as ready-to-use presentations in which the drugs and administration systems are self-contained and delivered at the point of care.

Cipla’s proven, hospital-focused sales and marketing organisation will be essential in introducing BioQ Pharma’s proprietary unit-dose, large volume infusion pharmaceuticals to India’s healthcare market.

Cipla Share Price

1494.90 -5.50 (-0.37%)
24-Dec-2025 11:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.20
Dr. Reddys Lab 1261.10
Cipla 1494.90
Zydus Lifesciences 918.20
Lupin 2105.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×